Skip to main content

Hims & Hers Health, Inc.

corporate_fare Company Profile

Hims & Hers Health, Inc.

HIMS·NYSE·Industrial Applications And Services·CIK 0001773751

Hims & Hers Health, Inc., launched in 2017, operates a consumer-focused platform that helps customers meet their health and wellness needs. The company provides a digital platform that includes access to a network of qualified healthcare providers, an electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization features. This platform enables access to treatments for various chronic conditions, such as sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, along with services like comprehensive laboratory testing. Hims & Hers connects patients with licensed healthcare professionals who can prescribe medications, including through personalized treatment plans, with prescriptions fulfilled online by licensed pharmacies. Additionally, the company offers a selection of non-prescription health and wellness products. Through its mobile applications, consumers can access educational programs, wellness content, community support, and other services. Since its founding, Hims & Hers has facilitated over fifty million telehealth consultations, providing access to care in the United States, Canada, the United Kingdom, and the European Union (specifically in Germany, the Republic of Ireland, France, and Spain). The company's strategy focuses on its brand, products and services, technology, and clinical excellence.

Hims & Hers Health, Inc. (NYSE:HIMS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors HIMS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Hims & Hers Shares Soar 40% on Reported Novo Nordisk Deal for Weight-Loss Drugs
  • Hims' Partner to Reintroduce Controversial GLP-1 Pill After Regulatory Halt
  • Hims & Hers Reports Strong 2025 Growth Amid Escalating Regulatory Scrutiny and Patent Lawsuit Over GLP-1 Products
  • Hims & Hers Reports Strong FY25 Revenue Growth, Mixed Q4 Profitability, and Issues FY26 Guidance
  • Hims & Hers to Acquire Eucalyptus for Up to $1.15B, Accelerating Global Digital Health Expansion

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.35B
Net Income
$128.37M
Diluted EPS
$0.51
Op. Cash Flow
$300.01M
Free Cash Flow
$57.41M
Gross Profit
$1.73B
Operating Income
$105.61M
Cash & Equivalents
$228.62M
Total Debt
$972.58M
Debt / Equity
1.80×
Net Margin
5.5%
Shares Outstanding
224.96M sh
Source: 10-K · filed 2026-02-23 · accession 0001773751-26-000022
$37.05 +0.25% today
52-week range · as of 2026-07-01 $13.74 – $70.43
Market cap
$8.52B
Volume
16.5M (0.9× avg)
3-mo avg 18.6M
Live data · 2026-07-05 03:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HIMS - Filings & News (Page 2)

HIMS
Mar 09, 2026, 7:43 AM EDT
Source: ShareCast
Importance Score:
9
Price at Filing: $22.35
Real-time Price: $37.05 info
Change: +$14.70 (+66%) info
Market Cap: $8.518B info
HIMS
Mar 03, 2026, 10:33 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $15.53
Real-time Price: $37.05 info
Change: +$21.52 (+139%) info
Market Cap: $8.518B info
HIMS
Feb 23, 2026, 5:20 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $15.20
Real-time Price: $37.05 info
Change: +$21.85 (+144%) info
Market Cap: $8.518B info
HIMS
Feb 23, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.90
Real-time Price: $37.05 info
Change: +$22.15 (+149%) info
Market Cap: $8.518B info
HIMS
Feb 19, 2026, 6:19 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $15.99
Real-time Price: $37.05 info
Change: +$21.06 (+132%) info
Market Cap: $8.518B info